Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,
and over the past six months, the industry has pulled back by 6.9%. This performance is a noticeable divergence from the S&P 500’s 5.8% return.
Medical technology company Stryker (NYSE:SYK) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 11.1% year on year to $6.02 billion. Its non-GAAP profit of $3.13 per share was 1.9% above analysts’ consensus estimates.
Since February 2025, Stryker has been in a holding pattern, posting a small loss of 3.8% while floating around $377.49. The stock also fell short of the S&P 500’s 4.5% gain during that period.
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner.
Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.
It's a rough start to the new month for Wall Street, as major U.S. stock indices plunged by midday Friday, setting the stage for a negative weekly close.
Medical technology company Stryker (NYSE:SYK) reported Q2 CY2025 results topping the market’s revenue expectations, with sales up 11.1% year on year to $6.02 billion. Its non-GAAP profit of $3.13 per share was 1.9% above analysts’ consensus estimates.
The stocks featured in this article have all approached their 52-week highs.
When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant industry tailwinds.
When Wall Street turns bearish on a stock, it’s worth paying attention.
These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.
